After a two-year process calling on New York State lawmakers to update patient protections surrounding biologic treatments, U.S. Pain Foundation is pleased to announce that Gov. Andrew Cuomo signed a biologic substitution bill, Chapter 357 of the Laws of 2017.
Earlier in the state’s legislative session, U.S. Pain reached out to senators and the Assembly, urging them to support Senate Bill 4788 and its companion bill. The legislation secured effective medication substitution laws while also allowing patients to access this new age of medicines in a safe, reliable, and consistent manner.
U.S. Pain Foundation spoke out on two important federal issues this month with articles in the National Pain Report. The first article, published Jan. 11, discussed the potential Affordable Care Act (ACA) repeal, while a second article highlighted new biosimilar and biologic naming guidelines and was published Jan. 24.
In the ACA story, U.S. Pain joined many other patient advocacy organizations in expressing concern over the potential repeal without details for a replacement. Written by Shaina Smith, director of advocacy and alliance development, on behalf of U.S. Pain, the article emphasized the importance of access to quality, affordable insurance for chronic pain patients.